The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Open accessAbstract
EZ Inhibition: Missense mutations in the core constituents of the genome packaging material, chromatin, have been implicated in several of human cancers. Nucleosomes are made up of histones, and a mutation of lysine 27 (K27) to methionine in the N-terminal tail of histone variants H3.3 and H3.1 has been identified in various pediatric gliomas. Lewis et al. (p. 857 , published online 28 March; see the Perspective by Morgan and Shilatifard ) show that the polycomb enzyme complex, which can epigenetically modify K27 by addition of a methyl group—and which is often a silencing signal—is itself potently inhibited by replacement of the H3.3/3.1 K27 by methionine. The inhibition of the EZH2 subunit causes an overall reduction of K27 methylation. Methionine mutants of other methylated lysine residues in histone H3 cause similar reductions in methylation levels of the cognate lysine, altering the epigenetic profiles of such cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, tumor cells with the K27M mutation exhibit low levels of H3K27me3 and aberrant gene silencing (4,(7)(8)(9).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Additional histone H3 lysine-to-methionine mutants possess dominant gain-of-function activities [6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“We and others previously showed that K-to-M oncohistones transform the histone H3 proteins into potent inhibitors of specific lysine methyltransferase enzymes (4-7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies showed that the K27M mutation found in pediatric glioma is sufficient to transform histone H3 into a potent inhibitor of enzymatic activity of PRC2 (4, 5, 7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“we previously showed that H3K9M peptides are capable of inhibiting activity of SUV39H1 and G9a, two H3K9-directed methyltransferases, in vitro (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previously, we found that only long, unbranched hydrophobic side chains containing methionine (M) and isoleucine (I) at lysine 27 (K27M and K27I) were capable of inhibiting PRC2 in vitro and decreasing H3K27me3 when expressed ectopically in cultured cells (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
In the citing paper
“Despite reports supporting a higher affinity of PRC2 for H3K27M as compared with wild-type H3 108-110 , H3K27M was often inversely correlated with PRC2 occupancy, challenging the idea that H3K27M sequesters PRC2 on chromatin 111,112 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [112]
In the citing paper
“Expression of the histone mutant is accompanied by a reduction in the levels of Polycomb Repressive Complex 2 (PRC2) mediated H3K27 trimethylation (H3K27me3) and this is purported to be a driving event of DIPG oncogenesis4,5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Interestingly upon loss of H3K27me3 these nucleosomes acquire H3K27ac resulting in the formation of H3K27M-K27ac heterotypic nucleosomes4 (Figure 1D and Supplementary Fig. 5B–C).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“As shown by our group and others, H3K27M expression is associated with increased levels of H3K27ac4,5 (Fig. 1D).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Although still functionally active, PRC2 catalytic property toward H3K27M containing nucleosomes is strongly inhibited4.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Collectively, these results strongly indicate that H3K27M in DIPG cells does not appear to recruit or sequester EZH2 (or in general PRC2), as suggested by other studies4,6,7.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Attempts to model H3.3K27M-driven HGG formation in vivo via genetic recombination in neural progenitor/stem cells (NPCs) in the postnatal brain failed to demonstrate tumor-driving activity”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
In the citing paper
“H3.3K27M has been shown to have gain-of-function activity inhibiting the Polycomb Repressive Complex 2 (PRC2) (Bender et al., 2013; Lewis et al., 2013), which in turn leads to a global reduction in H3K27me3 levels in primary tumors and tumor-derived primary cells.”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., & Patel, D. J. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1338 · Cited by 1,476
Self-citationRole of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., Voigt, P., Martin, S. R., Taylor, W. R., Marco, V. D., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,281
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 880
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 719
Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 633
A Novel Mammalian Flavin-dependent Histone Demethylase
Karytinos, A., Forneris, F., Profumo, A., Ciossani, G., Battaglioli, E., Binda, C., & Mattevi, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.003087 · Cited by 274
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 999
Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric gliomaPreprint
Lee, C., Yu, J.-R., Granat, J., Saldaña-Meyer, R., Andrade, J., LeRoy, G., Jin, Y., Lund, P. J., Stafford, J. M., Garcia, B. A., et al. (2019) · Genes & Development · doi:10.1101/gad.328773.119 · Cited by 123
Self-citationPiunti, A., Smith, E. R., Morgan, M. A., Ugarenko, M., Khalatyan, N., Helmin, K. A., Ryan, C., Murray, D. C., Rickels, R. A., Yilmaz, B. D., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax2887 · Cited by 110
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 111
Self-citationParental nucleosome segregation and the inheritance of cellular identity
Escobar, T. M., Loyola, A., & Reinberg, D. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00312-w · Cited by 109
Regulation of the Dot1 histone H3K79 methyltransferase by histone H4K16 acetylation
Valencia‐Sánchez, M. I., Ioannes, P. D., Wang, M., Truong, D. M., Lee, R., Armache, J., Boeke, J. D., & Armache, K. (2021) · Science · doi:10.1126/science.abc6663 · Cited by 112
An epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 106
A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
Bennett, R. L., Bele, A., Small, E. C., Will, C., Nabet, B., Oyer, J. A., Huang, X., Ghosh, R. P., Grzybowski, A. T., Yu, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0393 · Cited by 103
Endogenous mammalian histone H3.3 exhibits chromatin-related functions during development
Bush, K. M., Yuen, B. T. K., Barrilleaux, B. L., Riggs, J. W., O’Geen, H., Cotterman, R. F., & Knoepfler, P. S. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-7 · Cited by 108
Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment
Zhou, Z., Singh, R., & Souweidane, M. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160614093615 · Cited by 110
H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers
Dong, F., Gan, H., Cheng, L., Lee, J., Zhou, H., Sarkaria, J. N., Daniels, D. J., & Zhang, Z. (2018) · eLife · doi:10.7554/elife.36696 · Cited by 106
Major Features of the 2021 WHO Classification of CNS Tumors
Smith, H. L., Wadhwani, N. R., & Horbinski, C. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01249-0 · Cited by 110
Oncohistones: drivers of pediatric cancersPreprint
Mohammad, F., & Helin, K. (2017) · Genes & Development · doi:10.1101/gad.309013.117 · Cited by 106
Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression
Jain, S. U., Khazaei, S., Marchione, D. M., Lundgren, S. M., Wang, X., Weinberg, D. N., Deshmukh, S., Juretic, N., Lü, C., Allis, C. D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006076117 · Cited by 108
Self-citationOncohistone mutations enhance chromatin remodeling and alter cell fates
Bagert, J. D., Mitchener, M. M., Patriotis, A. L., Dul, B. E., Wojcik, F., Nacev, B. A., Feng, L., Allis, C. D., & Muir, T. W. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00738-1 · Cited by 102
Self-citationTanboon, J., Williams, E. A., & Louis, D. N. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv009 · Cited by 100
Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas
Fortin, J., Tian, R., Zarrabi, I., Hill, G., Williams, E., Sánchez‐Duffhues, G., Thorikay, M., Ramachandran, P., Siddaway, R., Wong, J. F., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.002 · Cited by 103
Structural basis for COMPASS recognition of an H2B-ubiquitinated nucleosome
Worden, E. J., Zhang, X., & Wolberger, C. (2020) · eLife · doi:10.7554/elife.53199 · Cited by 103
Jayaram, H., Hoelper, D., Jain, S. U., Cantone, N., Lundgren, S. M., Poy, F., Allis, C. D., Cummings, R., Bellon, S., & Lewis, P. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605523113 · Cited by 92
Self-citationHistone H3 mutations—a special role for H3.3 in tumorigenesis?
Kallappagoudar, S., Yadav, R. K., Lowe, B. R., & Partridge, J. F. (2015) · Chromosoma · doi:10.1007/s00412-015-0510-4 · Cited by 104
Gallo, M., Coutinho, F. J., Vanner, R. J., Gayden, T., Mack, S. C., Murison, A., Remke, M., Ren, L., Takayama, N., Desai, K., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.005 · Cited by 97
Yoshimoto, K., Hatae, R., Sangatsuda, Y., Suzuki, S. O., Hata, N., Akagi, Y., Kuga, D., Murata, H., Yamashita, K., Togao, O., et al. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0287-7 · Cited by 97
Arimura, Y., Ikura, M., Fujita, R., Noda, M., Kobayashi, W., Horikoshi, N., Sun, J., Shi, L., Kusakabe, M., Harata, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky661 · Cited by 98
Bryant, L. M., Li, D., Cox, S. G., Marchione, D. M., Joiner, E. F., Wilson, K., Janssen, K. A., Lee, P., March, M., Nair, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9207 · Cited by 98
Ezponda, T., & Licht, J. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2499 · Cited by 97
Mutations in chromatin machinery and pediatric high-grade glioma
Lulla, R. R., Saratsis, A. M., & Hashizume, R. (2016) · Science Advances · doi:10.1126/sciadv.1501354 · Cited by 99
The Histone Variant H3.3 in Transcriptional Regulation and Human Disease
Shi, L., Wen, H., & Shi, X. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.019 · Cited by 105
Harutyunyan, A. S., Chen, H., Lu, T., Horth, C., Nikbakht, H., Krug, B., Russo, C., Bareke, E., Marchione, D. M., Coradin, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108390 · Cited by 95
Self-citationHistone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase
Jani, K. S., Jain, S. U., Ge, E. J., Diehl, K. L., Lundgren, S. M., Müller, M. M., Lewis, P. W., & Muir, T. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819029116 · Cited by 99
Self-citationFlamier, A., Abdouh, M., Hamam, R., Barabino, A., Patel, N., Gao, A. Y. L., Hanna, R., & Bernier, G. (2020) · npj Precision Oncology · doi:10.1038/s41698-019-0106-1 · Cited by 94
Evidence of H3 K27M mutations in posterior fossa ependymomas
Gessi, M., Capper, D., Sahm, F., Huang, K. T. L., von Deimling, A., Tippelt, S., Fleischhack, G., Scherbaum, D., Alfer, J., Juhnke, B.-O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1608-3 · Cited by 93
Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation In Cis
Shi, L., Shi, J., Shi, X., Li, W., & Wen, H. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.014 · Cited by 95
Epigenetic regulators in cancer therapy and progression
Marei, H. E. S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01003-7 · Cited by 116
Schroeder, K., Hoeman, C. M., & Becher, O. J. (2013) · Pediatric Research · doi:10.1038/pr.2013.194 · Cited by 100
Self-citationSETting the Stage for Cancer Development: SETD2 and the Consequences of Lost MethylationPreprint
Fahey, C. C., & Davis, I. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026468 · Cited by 92
de Vries, N. A., Hulsman, D., Akhtar, W., de Jong, J., Miles, D. C., Blom, M., van Tellingen, O., Jonkers, J., & van Lohuizen, M. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.028 · Cited by 93
Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells
Wuputra, K., Ku, C., Wu, D., Lin, Y., Saito, S., & Yokoyama, K. K. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01584-0 · Cited by 103
BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis
Fan, H., Lu, J., Guo, Y., Li, D., Zhang, Z., Tsai, Y., Pi, W., Ahn, J. H., Gong, W., Xiang, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00729-3 · Cited by 95
Lu, V. M., Alvi, M. A., McDonald, K. L., & Daniels, D. J. (2019) · Journal of Neurosurgery Pediatrics · doi:10.3171/2018.9.peds18419 · Cited by 91
Mancarella, D., & Plass, C. (2021) · Genome Medicine · doi:10.1186/s13073-021-00837-7 · Cited by 91
ACVR1 Mutations in DIPG: Lessons Learned from FOP
Taylor, K. R., Vinci, M., Bullock, A. N., & Jones, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1298 · Cited by 95
Danussi, C., Bose, P., Parthasarathy, P. T., Silberman, P. C., Arnam, J. S. V., Vitucci, M., Tang, O. Y., Heguy, A., Wang, Y., Chan, T. A.-T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03476-6 · Cited by 91
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations
Miklja, Z., Pasternak, A. L., Stallard, S., Nicolaides, T. P., Kline-Nunnally, C., Cole, B., Beroukhim, R., Bandopadhayay, P., Chi, S. N., Ramkissoon, S. H., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz022 · Cited by 90
Context-dependent actions of Polycomb repressors in cancer
Koppens, M. A. J., & van Lohuizen, M. (2015) · Oncogene · doi:10.1038/onc.2015.195 · Cited by 88
Hall, M. D., Odia, Y., Allen, J. E., Tarapore, R. S., Khatib, Z. A., Niazi, T. N., Daghistani, D., Schalop, L., Chi, A. S., Oster, W., et al. (2019) · Journal of Neurosurgery Pediatrics · doi:10.3171/2019.2.peds18480 · Cited by 88
A novel histone H4 variant H4G regulates rDNA transcription in breast cancer
Long, M., Sun, X., Shi, W., An, Y., Leung, S. T. C., Ding, D., Cheema, M. S., Macpherson, N. A., Nelson, C. J., Ausió, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz547 · Cited by 93
Fasciani, A., D’Annunzio, S., Poli, V., Fagnocchi, L., Beyes, S., Michelatti, D., Corazza, F., Antonelli, L., Gregoretti, F., Oliva, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00724-8 · Cited by 87
Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesisPreprint
Wassef, M. A., Rodilla, V., Teissandier, A., Zeitouni, B., Gruel, N., Sadacca, B., Irondelle, M., Charruel, M., Ducos, B., Michaud, A., et al. (2015) · Genes & Development · doi:10.1101/gad.269522.115 · Cited by 95
Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis
Daoud, E. V., Rajaram, V., Cai, C., Oberle, R., Martin, G. R., Raisanen, J. M., White, C. L., Foong, C., Mickey, B., Pan, E., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly006 · Cited by 84
Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends
Hoang, S. M., & O’Sullivan, R. J. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.009 · Cited by 85
Persson, M. L., Douglas, A. M., Alvaro, F., Faridi, P., Larsen, M. R., Alonso, M. M., Vitanza, N. A., & Dun, M. D. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac117 · Cited by 85
The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79
Chen, S., Yang, Z., Wilkinson, A. W., Deshpande, A. J., Sidoli, S., Krajewski, K., Strahl, B. D., Garcia, B. A., Armstrong, S. A., Patel, D. J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.08.019 · Cited by 85
Self-citationGenomic Insights into Diffuse Intrinsic Pontine Glioma
Lapin, D. H., Tsoli, M., & Ziegler, D. S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00057 · Cited by 84
A basic motif anchoring ISWI to nucleosome acidic patch regulates nucleosome spacing
Dao, H. T., Dul, B. E., Dann, G. P., Liszczak, G., & Muir, T. W. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0413-4 · Cited by 85
Self-citationHaase, S., Banerjee, K., Mujeeb, A., Hartlage, C. S., Núñez, F. M., Núñez, F. J., Alghamri, M. S., Kadiyala, P., Carney, S. V., Barissi, M. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154229 · Cited by 89
Cohen, A. S. A., Yap, D., Lewis, M. E. S., Chijiwa, C., Ramos‐Arroyo, M. A., Tkachenko, N., Milano, V., Fradin, M., McKinnon, M. L., Townsend, K. N., et al. (2015) · Human Mutation · doi:10.1002/humu.22946 · Cited by 92
Morel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 87
Dhall, A., Wei, S., Fierz, B., Woodcock, C. L. F., Lee, T.-H., & Chatterjee, C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.591644 · Cited by 83
Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
Appin, C., & Brat, D. J. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000048 · Cited by 86
Findlay, I. J., Iuliis, G. N. D., Duchatel, R. J., Jackson, E. R., Vitanza, N. A., Cain, J. E., Waszak, S. M., & Dun, M. D. (2021) · Oncogene · doi:10.1038/s41388-021-02102-y · Cited by 86
Hypoxia drives transient site-specific copy gain and drug-resistant gene expressionPreprint
Black, J. C., Atabakhsh, E., Kim, J., Biette, K. M., Rechem, C. V., Ladd, B., Burrowes, P. D., Donado, C. A., Mattoo, H., Kleinstiver, B. P., et al. (2015) · Genes & Development · doi:10.1101/gad.259796.115 · Cited by 87
Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation
Zhang, Y., Shan, C., Wang, J., Bao, K., Tong, L., & Jia, S. (2017) · Scientific Reports · doi:10.1038/srep43906 · Cited by 87
Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants
Bressan, R. B., Southgate, B., Ferguson, K. M., Blin, C., Grant, V., Alfazema, N., Wills, J. C., Marqués‐Torrejón, M. Á., Morrison, G. M., Ashmore, J., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.016 · Cited by 88
Cutter, A. R., Taneja, N., Dhakshnamoorthy, J., Wheeler, D. L., Holla, S., & Grewal, S. I. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100699118 · Cited by 82
Aoshima, K., Inoue, E., Sawa, H., & Okada, Y. (2015) · EMBO Reports · doi:10.15252/embr.201439700 · Cited by 79
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
Katagi, H., Louis, N., Unruh, D. J., Sasaki, T., He, X., Zhang, A., Ma, Q., Piunti, A., Shimazu, Y., Lamano, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3890 · Cited by 84
Self-citationMichniewicz, F., Saletta, F., Rouaen, J. R. C., Hewavisenti, R., Mercatelli, D., Cirillo, G., Giorgi, F. M., Trahair, T. N., Ziegler, D. S., & Vittorio, O. (2021) · ChemMedChem · doi:10.1002/cmdc.202100172 · Cited by 81
Zha, L., Li, F., Wu, R., Artinian, L. R., Rehder, V., Yu, L., Liang, H., Xue, B., & Shi, H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.662650 · Cited by 80
Pfaff, E., Damaty, A. E., Balasubramanian, G. P., Blattner-Johnson, M., Worst, B. C., Stark, S., Witt, H., Pajtler, K. W., van Tilburg, C. M., Witt, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.019 · Cited by 78
Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets
Aziz‐Bose, R., & Monje, M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000577 · Cited by 82
Golbourn, B. J., Halbert, M. E., Halligan, K. E., Varadharajan, S., Krug, B., Mbah, N. E., Kabir, N., Stanton, A.-C. J., Locke, A. L., Casillo, S. M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00348-3 · Cited by 80
Jin, M., Cao, W., Chen, B., Xiong, M., & Cao, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.808859 · Cited by 88
Histone variants: nuclear function and disease
Zink, L.-M., & Hake, S. B. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.12.002 · Cited by 82
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells
Reitman, Z. J., Paolella, B. R., Bergthold, G., Pelton, K., Becker, S., Jones, R. E., Sinai, C. E., Malkin, H., Huang, Y., Grimmett, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11493-2 · Cited by 78
Invited Review: Epigenetics in neurodevelopment
Salinas, R. D., Connolly, D. R., & Song, H. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12608 · Cited by 90
Price, G. A., Bouras, A., Hambardzumyan, D., & Hadjipanayis, C. G. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103453 · Cited by 79
H3K36 trimethylation-mediated biological functions in cancer
Xiao, C., Fan, T., Tian, H., Zheng, Y., Zhou, Z., Li, S., Li, C., & He, J. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01187-2 · Cited by 63
Biomarker-driven diagnosis of diffuse gliomas
Appin, C., & Brat, D. J. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.002 · Cited by 84
Depletion of Nsd2-mediated histone H3K36 methylation impairs adipose tissue development and function
Zhuang, L., Jang, Y., Park, Y.-K., Lee, J., Jain, S., Froimchuk, E., Broun, A., Liu, C., Gavrilova, O., & Ge, K. (2018) · Nature Communications · doi:10.1038/s41467-018-04127-6 · Cited by 82
The dark side of histones: genomic organization and role of oncohistones in cancer
Amatori, S., Tavolaro, S., Gambardella, S., & Fanelli, M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01057-x · Cited by 85
Nie, X., Wang, H., Li, J., Holec, S., & Berger, F. (2014) · Biology Open · doi:10.1242/bio.20148680 · Cited by 79
Northcott, P. A., Pfister, S. M., & Jones, D. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71206-9 · Cited by 80
Emerging Roles of ATRX in Cancer
Watson, L. A., Goldberg, H. E., & Bérubé, N. G. (2015) · Epigenomics · doi:10.2217/epi.15.82 · Cited by 82
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 86
The evolving landscape of glioblastoma stem cells
Yan, K. K.-L., Yang, K., & Rich, J. N. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000032 · Cited by 83
Structure, mechanism, and regulation of polycomb-repressive complex 2
Moritz, L., & Trievel, R. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.800367 · Cited by 84
Grau, D., Zhang, Y., Lee, C., Valencia‐Sánchez, M. I., Zhang, J., Wang, M., Holder, M., Svetlov, V. V., Tan, D., Nudler, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20775-z · Cited by 77
Huang, T., García, R. M., Qi, J., Lulla, R. R., Horbinski, C., Behdad, A., Wadhwani, N. R., Shilatifard, A., James, C. D., & Saratsis, A. M. (2018) · Oncotarget · doi:10.18632/oncotarget.26430 · Cited by 77
Targeting epigenetic regulations in cancer
Ning, B., Li, W., Zhao, W., & Wang, R. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv116 · Cited by 77
Physical Nature of Chromatin in the NucleusPreprint
Maeshima, K., Iida, S., & Tamura, S. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a040675 · Cited by 81
Ren, Z., Ahn, J. H., Liu, H., Tsai, Y., Bhanu, N. V., Koss, B. S., Allison, D. F., Ma, A., Storey, A. J., Wang, P., et al. (2019) · Blood · doi:10.1182/blood.2019000578 · Cited by 76
Self-citationEverolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
Miklja, Z., Yadav, V. N., Cartaxo, R. T., Siada, R. G., Thomas, C., Cummings, J. R., Mullan, B. P., Stallard, S., Paul, A., Bruzek, A. K., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133310 · Cited by 75
Funato, K., Smith, R. C., Saito, Y., & Tabar, V. S. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.02.003 · Cited by 78
Halvorson, K. G., Barton, K. L., Schroeder, K., Misuraca, K. L., Hoeman, C. M., Chung, A., Crabtree, D., Cordero, F. J., Singh, R. B., Spasojević, I., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118926 · Cited by 77
Self-citationPoli, V., Fagnocchi, L., & Zippo, A. (2018) · Stem Cells International · doi:10.1155/2018/4598195 · Cited by 81
In situ chromatin interactomics using a chemical bait and trap approach
Burton, A. J., Haugbro, M., Gates, L. A., Bagert, J. D., Allis, C. D., & Muir, T. W. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0474-8 · Cited by 75
Self-citationHistone H2A T120 Phosphorylation Promotes Oncogenic Transformation via Upregulation of Cyclin D1
Aihara, H., Nakagawa, T., Mizusaki, H., Yoneda, M., Kato, M., Doiguchi, M., Imamura, Y., Higashi, M., Ikura, T., Hayashi, T., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.012 · Cited by 74
Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
Korfhage, J. L., & Lombard, D. B. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0147 · Cited by 78
Khazaei, S., Jay, N. D., Deshmukh, S., Hendrikse, L. D., Jawhar, W., Chen, C. C. L., Mikael, L. G., Faury, D., Marchione, D. M., Lanoix, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0461 · Cited by 76
Self-citationInhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma
Voon, H. P. J., Udugama, M., Lin, W., Hii, L. L., Law, R. H. P., Steer, D. L., Das, P. P., Mann, J. R., & Wong, L. H. (2018) · Nature Communications · doi:10.1038/s41467-018-05607-5 · Cited by 79
Williams, J. R., Young, C. C., Vitanza, N. A., McGrath, M., Feroze, A. H., Browd, S. R., & Hauptman, J. S. (2020) · Neurosurgical FOCUS · doi:10.3171/2019.9.focus19745 · Cited by 75
Metadata
- Authors
- Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D.
- Affiliations
- Rockefeller University (US)
- Princeton University (US)
- Duke University (US)
- University of Pennsylvania (US)
- Corresponding author
- Allis, C. David
- ORCID
- Venue
- Science
- Published
- 2013-05-17
- Volume
- 340
- Issue
- 6134
- Pages
- 857-861
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3951439
- OpenAlex
- W1995105508
- Cited by
- 1,345
- References
- 14
- Citations by year
- 2026: 73 · 2025: 82 · 2024: 103 · 2023: 106 · 2022: 103 · 2021: 118 · 2020: 146 · 2019: 112 · 2018: 84 · 2017: 102 · 2016: 90 · 2015: 95 · 2014: 87 · 2013: 40
- FWCI
- 51.21
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- National Institutes of Health (DP2OD007447)
- National Institute of Mental Health (P50MH096890)
- National Institute of General Medical Sciences (GM040922, R01GM107047, R01GM040922)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pediatric glioblastoma, diffuse intrinsic pontine glioma, H3K27M mutation, histone H3.3, H3K27me3, polycomb repressive complex 2, EZH2, histone methylation, gain-of-function mutations, epigenetic regulation
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Brain Neoplasms, Child, Glioblastoma, Histones, Humans, Lysine, Methionine, Methylation, Transgenes, Amino Acid Substitution, Mutation, Missense, Epigenesis, Genetic, Mice, HEK293 Cells, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
